about
Experience with biosimilar infliximab (CT-P13) in paediatric patients with inflammatory bowel diseasesEfficacy and Safety of Lactobacillus plantarum DSM 9843 (LP299V) in the Prevention of Antibiotic-Associated Gastrointestinal Symptoms in Children-Randomized, Double-Blind, Placebo-Controlled Study.Autoimmune markers in children with chronic pancreatitis.High- and low-dose oral delayed-release mesalamine in children with mild-to-moderately active ulcerative colitisGene conversion between cationic trypsinogen (PRSS1) and the pseudogene trypsinogen 6 (PRSS3P2) in patients with chronic pancreatitis.Efficacy and safety of mesalamine suppositories for treatment of ulcerative proctitis in children and adolescents.Efficacy and Safety of Adalimumab for Paediatric Crohn's Disease: A Systematic Review.Histological healing after infliximab induction therapy in children with ulcerative colitisThe protocol for a randomised-controlled trial of the evaluation of the tolerance and safety of early enteral nutrition in children after percutaneous endoscopic gastrostomy placement. (protocol version 09.01.2015).Safety profile of biologic therapy in Polish paediatric patients with Crohn's disease.Efficacy and Safety of Escalation of Adalimumab Therapy to Weekly Dosing in Pediatric Patients with Crohn's Disease.Diagnosis of gastroesophageal reflux and anti-reflux procedures among Polish children with gastrostomies: a 10-year nationwide analysis.Genetic architecture differences between pediatric and adult-onset inflammatory bowel diseases in the Polish population.Comparative safety and efficacy of proton pump inhibitors in paediatric gastroesophageal reflux disease.Enteric-coated budesonide for the induction and maintenance of remission of Crohn's disease in children.Induction Therapy With Biosimilar Infliximab in Children With Crohn Disease.Demographic characteristics of children with early clinical manifestation of inflammatory bowel disease.Adalimumab for endoscopic and histopathological mucosal healing in paediatric patients with moderate to severe Crohn's disease.European Crohn's and Colitis Organisation Topical Review on Transitional Care in Inflammatory Bowel Disease.Maintenance of efficacy and safety of rabeprazole in children with endoscopically proven GERD.Efficacy and safety of rabeprazole in children (1-11 years) with gastroesophageal reflux disease.The impact of induction therapy with three doses of infliximab on deep histological healing in paediatric patients with active Crohn's disease.The Etiology and Clinical Course of Chronic Pancreatitis in Children With Early Onset of the Disease.The clinical course of hereditary pancreatitis in children - A comprehensive analysis of 41 cases.Gastrointestinal disorders next to respiratory infections as leading symptoms of X-linked agammaglobulinemia in children - 34-year experience of a single center.Complications of PEG are not related to age - The result of 10-year multicenter survey.European Crohn's and Colitis Organisation Topical Review on Treatment Withdrawal ('Exit Strategies') in Inflammatory Bowel Disease.Phenotypic characterization of very early-onset IBD due to mutations in the IL10, IL10 receptor alpha or beta gene: a survey of the Genius Working Group.Randomized, open-label, multicentre pharmacokinetic studies of two dose levels of pantoprazole granules in infants and children aged 1 month through <6 years with gastro-oesophageal reflux disease.Pharmacodynamics and safety of pantoprazole in neonates, preterm infants, and infants aged 1 through 11 months with a clinical diagnosis of gastroesophageal reflux disease.The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus.Efficacy and safety of pantoprazole delayed-release granules for oral suspension in a placebo-controlled treatment-withdrawal study in infants 1-11 months old with symptomatic GERD.Evaluation of the effectiveness of biofeedback therapy for functional constipation in children.High- versus low-volume polyethylene glycol plus laxative versus sennosides for colonoscopy preparation in children.Hydrolyzed versus nonhydrolyzed protein diet in short bowel syndrome in children.Induction and maintenance infliximab therapy in children with moderate to severe ulcerative colitis: Retrospective, multicenter study.Home parenteral nutrition in children: the Polish experience.Dexlansoprazole for Heartburn Relief in Adolescents with Symptomatic, Nonerosive Gastro-esophageal Reflux Disease.Is growth hormone a feasible adjuvant in the treatment of children after small bowel resection?Research Gaps in Diet and Nutrition in Inflammatory Bowel Disease. A Topical Review by D-ECCO Working Group [Dietitians of ECCO].
P50
Q28066776-E4A498DC-7C82-477B-9182-2E66717EAAD2Q33470361-26B56105-1AE2-40CD-B36C-5C78FC50B313Q33947438-E602966A-6C14-4124-9043-2EEF63C2DAD4Q34631685-DC6EF8AA-788D-4C0A-840C-3DD753C0F7EAQ35181335-8240007F-9B09-4CA6-8F98-81A27EF2F459Q35654665-6B9ACB07-4CF3-4D86-A71E-7DC3E7475D6BQ35963837-A297DEAB-985E-4B2D-8666-1DAF3A02F146Q36105637-33931D3E-2233-41BD-B212-A46E5B3762E2Q36158016-93A04367-6B47-4036-93CA-0918C4CD9455Q36167373-E8E53D14-1A6C-43ED-BE32-A719EF74E8F1Q36692562-B1132823-BE99-4447-8541-AB18FAFD07BFQ37501793-B6967DA6-B52C-4A56-9DDE-9DF3B3FCF221Q37529278-2D301BDC-D443-4463-AB5F-783B6B01575FQ38202595-8689FCC5-5631-4F87-B7BC-892E2AB683E0Q38377938-6D469556-C058-47B3-9F4A-F2194CC1C1E5Q38765158-1A239998-1587-4D52-9596-6BDCFA36037EQ38816412-48298F49-4441-41BE-8095-659BFAA2A54CQ38880732-6D07841E-9129-4F75-8F28-08F59C166A01Q39118078-A253104A-A9F8-4741-BC50-9E01EED4825AQ39218255-B85095F7-46E4-4EE8-82C5-31EFA4D1A52BQ39223688-20D75BB4-C256-48C4-98A2-088D9E714151Q39314651-4363F8DC-18B2-4BE3-B06E-57CA458145A1Q39347254-E66D5C6D-776A-456A-8326-2211803B96A3Q39765913-ABD29EEE-D9BB-4503-9289-B68B18E61985Q40307695-014141E3-9043-4C3C-A0F4-46353F322D52Q40570344-89B38685-934A-43D7-B7C0-3F569CC29C99Q41990807-E0E5DC42-968A-4DB4-9754-C4B6ACCEF452Q42256398-8A907863-911C-431F-A4DB-E9588D1D9070Q42608396-113F936D-62A3-41F7-B65A-70F936E6B2AAQ42666948-1EE83190-A503-471F-BAE6-1E8DF015C6C1Q43046668-9FFA595A-3C8B-4D68-B79A-2754255B30FCQ43094738-014B1449-4645-4DFF-A26C-31A0BE3F5F62Q43355820-CF69BEFC-F805-4555-A19F-EDC5333143DDQ43357253-2E4AA907-222D-43DB-A120-F3ACEE756707Q44231441-E49E510B-F60C-4441-B1BF-C904E1377E40Q44380350-F5B957B3-E611-4734-8669-CEE7FB8A4CC4Q45163595-9388A2E9-35AE-4321-834B-2F695619B8C4Q47108611-C964FD3C-48DE-44A7-96C1-C70B84DC803DQ47903341-55A7467F-4F83-454B-B123-4F8AD57BBDF6Q47923338-C81ACE09-192F-4035-94C9-41CBA12C5205
P50
description
researcher ORCID ID = 0000-0003-2272-1581
@en
name
Jaroslaw Kierkus
@ast
Jaroslaw Kierkus
@en
Jaroslaw Kierkus
@es
Jaroslaw Kierkus
@ga
Jaroslaw Kierkus
@nl
Jarosław Kierkuś
@ca
Jarosław Kierkuś
@cs
Jarosław Kierkuś
@gl
Jarosław Kierkuś
@hr
Jarosław Kierkuś
@hsb
type
label
Jaroslaw Kierkus
@ast
Jaroslaw Kierkus
@en
Jaroslaw Kierkus
@es
Jaroslaw Kierkus
@ga
Jaroslaw Kierkus
@nl
Jarosław Kierkuś
@ca
Jarosław Kierkuś
@cs
Jarosław Kierkuś
@gl
Jarosław Kierkuś
@hr
Jarosław Kierkuś
@hsb
prefLabel
Jaroslaw Kierkus
@ast
Jaroslaw Kierkus
@en
Jaroslaw Kierkus
@es
Jaroslaw Kierkus
@ga
Jaroslaw Kierkus
@nl
Jarosław Kierkuś
@ca
Jarosław Kierkuś
@cs
Jarosław Kierkuś
@gl
Jarosław Kierkuś
@hr
Jarosław Kierkuś
@hsb
P214
P1153
6603311337
P1412
P1559
Jarosław Kierkuś
@pl
P21
P214
P27
P31
P3124
P496
0000-0003-2272-1581
P735
P7859
viaf-315216359